To The Moon

In the stock market, you don’t need to bet everything on expensive stocks to invest in quality companies. There are still solid options available at reasonable prices, like $Exelixis(EXEL)$ , which is currently trading below $40.Major Wins for ExelixisExelixis is a biotechnology company focused on oncology, with its most important product being Cabometyx, used to treat renal cell carcinoma (a type of kidney cancer) and hepatocellular carcinoma (liver cancer).Cabometyx has been the cornerstone of Exelixis’s revenue for some time. In Q2, its revenue grew 35.6% year-over-year, reaching $637.2 million. Cabometyx alone accounted for $437.6 million in the U.S., making up nearly 69% of the company's total revenue.While relying heavily on one product carr

On October 30, $Meta Platforms, Inc.(META)$ will release its Q3 2024 earnings report. Overall, the results are expected to be solid, offering enough reasons for the stock to maintain its strength—at least on the surface.But beyond logic, other forces are driving the stock and market. Even though Meta might continue showing decent relative growth, analysts aren’t optimistic about further gains. Why? Revenue growth is slowing, expenses are rising, and the stock is already hitting record highs.2025 Outlook: AI Investments and Growth SlowdownOnce 2025 comes into focus and massive AI investments start weighing on the balance sheet, things won’t be so easy. Revenue growth is naturally slowing after the strong gains of the past two years. Meta’s path for

Many healthcare stocks offer attractive dividends, but some high-yield options are worth considering, while others come with higher risks.1. $Pfizer(PFE)$ Some investors might think Pfizer is a stock to avoid, especially after its recent performance. The stock has dropped over 50% from its late 2021 peak, and though it has seen a slight recovery this year, it lags far behind $.SPX(.SPX)$ .The main reason for Pfizer's struggles? Its COVID-19 vaccine, Comirnaty. It generated $37.8 billion in sales in 2022 but is expected to drop to just $5 billion by 2024. Plus, Pfizer faces a looming patent cliff, with multiple drug patents expiring soon.Despite these challenges, Pfizer's forward dividend yield is a solid 5

Ryan_Z0528: +175% on $OKLO in 22 Days , The electricity value train：https://x.com/EricFlaningam/status/1848009956961685536 Investors are flocking to power-related stocks, and California-based advanced nuclear systems developer $Oklo Inc.(OKLO)$ has seen its stock price double, skyrocketing by 115% to a record high of $19.72, peaking at $20.64 and giving it a market cap of over $2.4 billion.Oklo went public in May through a merger with the special purpose acquisition company (SPAC) AltC Acquisition, experiencing volatile stock movements since then. The nuclear stock had fallen to a low of $5.35 on September 9 but has jumped over 200% in the past six weeks.Oklo is working on developing small modular reactors (SMRs) and plans to deliver its first rea

The GLP-1 weight-loss drug market is massive, but the competition is fierce. Instead of joining the race, Swiss pharma giant $Novartis AG(NVS)$ is playing it smart, focusing on more strategic growth areas.Novartis is sticking to what it’s good atCEO Vas Narasimhan recently said in an interview that the company has no plans to jump into the "crazy" weight-loss market, claiming they’ve got better options. He’s aiming to invest in projects with bigger potential payoffs, like radioligand cancer therapies, which could bring in up to $20 billion.Novartis is also eyeing other opportunities in treatments for Parkinson's, Huntington's, and Alzheimer’s diseases. Compared to the ultra-competitive weight-loss field, these areas might offer more solid ground fo

$Eli Lilly(LLY)$ is now one of the most valuable healthcare companies globally, boasting a market cap of over $800 billion. With its stock price surging more than 50% in the past 12 months, some investors may feel hesitant due to its price-to-earnings (P/E) ratio exceeding 100 times. However, there are strong reasons to consider Eli Lilly despite the high valuation. Here are three factors that suggest its valuation could continue to climb in the coming months and years:1. Tirzepatide's Undervalued PotentialEli Lilly has seen major success with FDA approvals, notably for the weight-loss drug Zepbound and the diabetes drug Mounjaro, both containing the same active ingredient: tirzepatide. These drugs are in the early stages of their growth cycles, an

Historically, small-cap stocks have thrived once the Fed begins cutting rates. Globally, markets in Japan, China, and the UK currently offer attractive valuations, providing interesting opportunities for investors.Small and Mid-Cap Stocks: Poised for GainsAccording to Brian G. Belski, chief investment strategist at BMO Capital Markets, valuations for small-cap and mid-cap stocks are appealing for investors looking to increase exposure. Data shows that small-cap stocks (S&P SmallCap 600) are still trading below their 20-year average, while mid-cap stocks (S&P MidCap 400) are only slightly above it. In contrast, the $.SPX(.SPX)$ is trading well above its 20-year average.Since 1995, in the year following the Fed’s first rate cut, the S&P

The agriculture sector is a huge opportunity, and if you're looking to grow your capital by investing in just-in-demand, innovative industries, these select U.S. agriculture stocks and exchange-traded funds (ETFs) may help you capitalize on this global trend.1. $Corteva, Inc.(CTVA)$ CTVA is a pure-play agriculture stock with a $39 billion market cap. The company leads the global market in seeds and crop protection products. Its seed division uses cutting-edge biotech to develop seeds that resist harsh weather, diseases, and pests while improving water efficiency. It also offers digital tools to help farmers make better decisions. With optimistic ratings from Morgan Stanley, Morningstar, and CFRA Research, CTVA has a forward dividend of $0.68 per s

As the $.SPX(.SPX)$ approaches its all-time high, some undervalued components like $Pfizer(PFE)$ $AbbVie(ABBV)$ are flying under the radar. Both of these healthcare stocks boast dividend yields over 3% and are poised for further increases, making them likely candidates to outperform the S&P 500 in the next decade.1. $Pfizer(PFE)$Last December, Pfizer raised its dividend for the 15th consecutive year, with a current yield of 5.8%. Even without additional hikes, this stock can provide substantial passive income. With many new patented drugs in the pipeline, investors can reasonably expect steady quarterly dividend increa

October is generally not considered the best time to invest in U.S. stocks. Historically, this month has seen declines and even market crashes. However, investing in resilient companies that can weather bull and bear markets is always wise. This includes biotech stocks.Let’s take a closer look at two biotech firms that fit this description: $Amgen(AMGN)$ and $Vertex Pharmaceuticals(VRTX)$.1. $Amgen(AMGN)$ Amgen has faced revenue challenges in recent years. In Q2, the company reported a 20% increase in revenue to $8.4 billion. However, excluding the impact of its acquisition of Horizon Therapeutics, organic growth was just 5%. While this is decent for a biotech gi